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Background. -e purpose of this study was to gather information on the current assessment and management of patients with
moderate-to-severe AD in routine daily practice. Methods. A cross-sectional two-round Delphi survey with the participation of
dermatologists and allergologists throughout Spain was conducted. -ey completed a 46-item questionnaire, and consensus was
defined when responses of ≥80% of participants coincided in the categories of a 5-point Likert scale for that item. Results. A total of
105 specialists (aged 40–59 years) completed the two rounds. Participants agreed regarding the consideration of AD as a
multifaceted disease and the differences in clinical presentation of AD according to the patient’s age. It is recommendable to
perform a skin biopsy to exclude early stage T-cell cutaneous lymphoma, psoriasis, or dermatitis herpetiformis, among others
(99.1%). Also, consensus was reached regarding the use of the SCORAD index to quantify the severity of the disease (86.7%), the
use of wet wraps to increase the effect of topical corticosteroids (90.4%), the usefulness of proactive treatment during follow-up
(85.6%) and tacrolimus ointment (91.2%) to reduce new flares, and the fact that crisaborole is not the treatment of choice for
severe AD (92.4%). AD was not considered a contraindication for immunotherapy in patients with allergic respiratory diseases
(92.4%). In patients with severe AD, the use of immune response modifier drugs (97.6%) or phototherapy (92.8%) does not
sufficiently cover their treatment needs. Consensus was also obtained regarding the role of the new biologic drugs (93.6%)
targeting cytokines involved in the-2 inflammatory pathway (92.0%) and the potential role of dupilumab as first-line treatment
(90.4%) in moderate-to-severe AD patients. Conclusion. -is study contributes a reference framework to the care of AD patients.
-ere is no diagnostic test or biomarkers to direct treatment or to assess the severity of the disease, and many therapeutic
challenges remain.
1. Introduction
Atopic dermatitis (AD) is a chronic, pruritic, relapsing
inflammatory skin condition, commonly affecting children
and, to a lesser extent, adults. Infants with ADmay develop a
typical progression of atopic disorders, including allergic
rhinitis, food allergy, and asthma at certain ages, a sequence
commonly referred to as the atopic march [1, 2]. AD
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diagnoses are continuously on the rise, oscillating between
10% and 20% of the pediatric population. -e disease affects
1–10% of adults worldwide, and recent studies have sug-
gested that adult AD is more common than previously
thought [3, 4]. Although AD is not a life-threatening con-
dition, it poses a significant social, psychological, and eco-
nomic burden [5]. -e negative psychosocial impact of AD
on quality of life is well established [5, 6], with itching,
scratching, sleep loss, and social embarrassment being
among the most commonly reported difficulties contrib-
uting to school, work, and social struggles. Depression and
anxiety have been reported to be also more common in
adults with AD, with these psychiatric symptoms being
influenced by AD disease severity and the degree of im-
pairment of quality of life [6].
-e presentation of AD depends on age and ranges from
papulovesicles to lichenified plaques. -e pathogenesis of
AD is multifactorial, including genetic, and environmental
factors. Also, AD is characterized by skin barrier defects,
immunologic dysfunction, and alterations in the skin
microbiome [7–9]. However, a number of cytokines and
mediators involved in -2, -22, -17, and -1 pathways
appear to be important in AD pathogenesis, and there is
currently an increasing interest in developing targeted
therapies, especially for patients with moderate-to-severe
forms of the disease not responding to conventional treat-
ments [10–12]. Also, the disease is frequently associated with
other comorbid skin conditions and extracutaneous diseases
[13, 14]. -e causative mechanisms underlying these asso-
ciations are poorly understood, but treating physicians
should be aware of these associations while seeking to al-
leviate the burden for patients with AD [15].
Available evidence on different aspects of the disease is
uncertain and scarce at the population level. -ere are two
studies on the prevalence of severe AD in adults in Spain,
one in three different areas (Asturias, Catalonia, and the
Balearic Islands) in 2015-2016 and the other one in Madrid
in 2016-2017; the estimated prevalence was 0.08% and
0.028% (0.015% for children), respectively [16, 17]. AD was
considered severe when the patient received a systemic
immunosuppressant or a biologic (omalizumab, rituximab)
during follow-up or had been hospitalized because of AD
[16]. However, presently, there exists no gold standard for
evaluating the severity of AD [18].
A study based on data from the 2016 National Health
and Wellness Survey conducted in France, Germany, Italy,
Spain, and the United Kingdom revealed that AD is asso-
ciated with a significant disease burden and higher preva-
lence of atopic and psychological comorbidities, impaired
health-related quality of life, lower work productivity, in-
creased activity impairment, and increased healthcare uti-
lization [19].-e Spanish Society of Allergology and Clinical
Immunology carried out two wide-scale studies regarding
the epidemiologic, clinical, and socioeconomic factors of the
main allergic disorders in Spain, including AD [20, 21].
However, no previous studies have evaluated the clinical
approach to patients with AD at a national level in Spain.
-erefore, a cross-sectional Delphi survey was designed to
gather information on the assessment and management of
patients with moderate-to-severe AD in conditions of
routine clinical practice. -e results of this study will be
helpful to identify some of the unmet medical needs cur-
rently present in the care of these patients.
2. Methods
2.1. Study Design. A cross-sectional two-round Delphi
survey was conducted over a 5-month period (between July
13 and December 5, 2017) with the participation of der-
matologists and allergologists throughout Spain. -e ob-
jective of the study was to develop a consensus document on
the clinical approach to moderate-to-severe AD patients.
-e aims of the consensus were as follows: (a) to help cli-
nicians in the assessment andmanagement of AD patients in
daily practice, (b) to know the current status of the care of
patients with AD in Spain, and (c) to identify potential areas
to improve outcomes, including early recognition of hall-
mark signs and symptoms to ensure correct diagnosis and
use of evidence-based tools to determine disease impact and
guide treatment decisions, and to promote patient en-
gagement and adherence to therapies.
-e Delphi method is generally accepted as a powerful
means of reaching consensus and generating ideas among
responders on a number of issues related to health problems
in conditions of low grade evidence, knowledge, or appli-
cation [22]. Briefly, the method involves sending a ques-
tionnaire to the responders and analyzing their response.
-is is then used to develop a new questionnaire and the
cycle is repeated. -ree methodological aspects are impor-
tant in a Delphi study. First, responders or panelists are not
aware of the identity of the other responders, to ensure that
their responses are independent. Second, participants re-
spond individually to avoid group domination by certain
individuals. -ird, mathematical voting procedures are used
to permit the ranking of items. Likewise, there are no set
guidelines for deciding on the optimum number of Delphi
participants as this is likely to change depending on the
purpose of the Delphi survey. -e original Delphi method
involves three or more rounds, whereas the modified
technique is limited to two rounds to avoid losses of ac-
ceptable response rates due to prolonged duration of the
process and the negative influence on the interest of the
panelists. In the present study, a modified Delphi method
was used to reach consensus.
2.2. Participants and Procedures. At the beginning of the
project, a scientific committee formed by nine specialists,
five dermatologists, and four allergologists with proven
experience and interest in AD was established. Participants
were authors of relevant research publications and were
renowned professionals in the care of allergic patients, with
expertise in AD. Two study coordinators (JS, ES) supervised
the progression of the study, including recruitment of
participants and results of analysis of data, as well as other
organizational and logistic aspects of the project.
Items to be included in the study questionnaire were
selected by members of the scientific committee based on a
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search of the literature to identify previously conducted
studies with high level of evidence, such as systematic re-
views and meta-analyses, and key primary studies focused
on the field of moderate-to-severe AD in adult patients.
Candidates to participate in the study were proposed by the
study coordinators andmembers of the scientific committee.
-ey were specialists in dermatology or allergology involved
in the care of patients with AD in public hospitals and some
private consultations throughout Spain, preferably with 5 or
more years of experience and attending at least 10 patients
with AD per month. -e study questionnaire was lodged in
an Internet microsite to which specialists who agreed to
participate accessed via a weblink with the user’s password.
-e initial draft included 47 items, two of which were
removed after the first round and a new item was added.
-erefore, the final questionnaire was composed of a set of
46 items, in which questions were grouped into seven
sections: definition and diagnosis (14 items), differential
diagnosis (1 item), severity of AD (2 items), etiology and
physiopathology (4 items), comorbidities of AD (4 items),
health-related quality of life (2 items), and treatment and
follow-up (19 items). Questions were formulated so that they
could be answered using a 5-point Likert scale: 1: “strongly
disagree,” 2: “disagree,” 3: “neither agree nor disagree,” 4:
“agree,” and 5: “strongly agree.” -e study questionnaire is
described in the Supplementary Materials.
2.3. Statistical Analysis. Only full completed questionnaires
were considered. -e consensus criteria included “una-
nimity” when 100% of the participants agreed on the same
category of the Likert scale, “consensus” when agreement
involved ≥80% of the participants, “majority” when agree-
ment involved ≥70% of participants, and “discrepancy”
when agreement involved <70% of the participants. For the
purpose of the analysis, “unanimity” and “consensus”
groups were considered together as a consensus. Descriptive
statistics included frequencies and percentages. -e analysis
was carried out trough consultation and analysis of the
answers in the database from the online platform.
3. Results
3.1. Characteristics of Participants. Of a total of 200 der-
matologists and allergologists who were invited to partici-
pate in the study, 125 (62.5%) accepted and completed the
first Delphi round, 105 (84%) of which completed the second
round. -e final participation rate was 52.5%. Of the 105
participants, 59 (56.2%) were dermatologists and 46 (43.8%)
allergologists. -e general profile of participants included a
mean age between 40 and 59 years, 5 or more than 5 years of
experience in the care of patients with AD with at least 10
patients with AD visiting per month (both children and
adults), and 46.7% working in public hospitals, with all of
them having available biologic drugs in the workplace.
3.2.General Results. After the two Delphi rounds, consensus
was reached on 36 of the 46 items (78.3%). -ere were 3
items where the agreement involved ≥70% of the
participants (6.5%) and there was discrepancy in 7 items
(15.2%). As shown in Table 1, the percentages of consensus
ranged between 50% and 100%, with the lowest percentages
being in the sections of severity of AD and comorbidities and
the highest percentages in the sections of differential diag-
nosis, etiology and physiopathology, and quality of life.
3.3.DefinitionandDiagnosis ofAD. Of the 14 items included
in this section, 12 (85.7%) achieved consensus, and there was
discrepancy in the remaining 2 (14.3%) (Table 2). Partici-
pants agreed regarding the consideration of AD as a mul-
tifaceted disease derived from the interaction of multiple
factors, including the skin components (96.8%), the immune
system (97.6%), skin microbiome (89.6%), and genetic
(98.4%) and environmental (98.4%) factors. AD is diagnosed
clinically (97.6%) using the criteria of Hanifin and Rajka
(94.3%), with the clinical presentation depending on the
patient’s age (92.8%), and currently lacking validated bio-
markers that can help in the diagnosis of AD (83.2%). -ere
were discrepancies in the usefulness of the classification of
intrinsic and extrinsic AD as the basis of specific avoidance
strategies (60%) and eosinophil count as a biomarker of AD
(37.1%).
3.4. Differential Diagnosis. Participants agreed on the single
item of this section, i.e., performing a skin biopsy to exclude
other conditions, such as early stage T-cell cutaneous
lymphoma, psoriasis, or dermatitis herpetiformis (99.1%)
(Table 3).
3.5. Severity of AD. Of the two items, consensus was reached
on one regarding the use of the SCORAD (scoring atopic
dermatitis) index to quantify the severity of the disease
(86.7%). -ere was discrepancy about eczema area and
severity index (EASI) score as a validated scale that is not
used in routine clinical practice (58.1%) (Table 3).
3.6. Etiology and Physiopathology. Of the four items, con-
sensus was reached in all of themwith the highest percentages
regarding that “currently there is an unmet need in the
treatment of moderate-severe AD” (98.4%) and the statement
that “a high percentage of patients with AD also present food
allergy, allergic rhinitis, or asthma” (94.4%) (Table 3).
3.7. Comorbidities. Of the four items, two achieved con-
sensus regarding the fact that DA in children is frequently
associated with allergic comorbidities (91.4%) and that
children with AD are more prone to suffer from mental
disorders (84.8%). -ere was no consensus about the as-
sociation of AD in adults with allergic disorders (78.1%) and
a higher relative risk for immune-mediated inflammatory
diseases (43.8%) (Table 3).
3.8. Health-Related Quality of Life. Consensus was reached
in the two items regarding AD as a cause of marked psy-
chological anxiety (91.2%) and the usefulness of patient-
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oriented SCORAD (PO-SCORAD) for the self-assessment of
AD in children, integrating the perspectives of the physician
and the patient in the management of the disease (91.2%)
(Table 3).
3.9. Treatment and Follow-Up. Of the 19 items regarding
different aspects of treatment and follow-up of patients with
AD, 14 (73.7%) obtained consensus, whereas most partic-
ipants agreed on 2 items (10.5%) and there were discrep-
ancies in 3 (15.8) (Table 4). In the presence of positive prick
tests, participants agreed on avoidance of suspected allergens
(83.8%) and dietary foods (91.4%). -ere was consensus on
the use of wet wraps to increase the effect of topical cor-
ticosteroids (90.4%), the usefulness of proactive treatment
during follow-up (85.6%) and tacrolimus ointment (91.2%)
to reduce new flares, and the fact that crisaborole is not the
treatment of choice for severe AD (92.4%). Most of the
participants (72.4%) believed that the simultaneous com-
bination on the same location of topical glucocorticoids and
topical calcineurin inhibitors is not useful. Also, there was
consensus that there are no enough bibliographic references
supporting the use of antihistamines to alleviate pruritus
(85.7%) but there was discrepancy regarding the usefulness
of antihistamines as systemic treatment of AD (64.8%). Most
participants agreed on the positive effects of allergen-specific
immunotherapy (SIT) in some sensitized patients (76.2%)
and reached consensus that the item of AD is not a con-
traindication for immunotherapy in patients with allergic
respiratory diseases (92.4%). In patients with severe AD, the
use of immune response modifier drugs (97.6%) or pho-
totherapy (92.8%) does not sufficiently cover their treatment
needs. Participants agreed on the adequate risk-benefit ratio
of cyclosporine (80.0%) but disagreed on the adequate risk-
benefit ratio of phototherapy (69.5%). Finally, there was
consensus on the role of the new biologic drugs (93.6%)
targeting cytokines involved in the -2 inflammatory
pathway (92.0%) and the potential role of dupilumab as
first-line treatment (90.4%) in moderate-to-severe AD
patients. By contrast, there was discrepancy regarding the
position of Janus kinase (JAK) inhibitors in the treatment
of AD (60.0%).
Table 1: General results obtained for the different sections of the questionnaire.
Section Items n Consensus n (%) Majority n (%) Discrepancy n (%)
1. Definition and diagnosis 14 12 (85.7) 0 2 (14.3)
2. Differential diagnosis 1 1 (100) 0 0
3. Severity of AD 2 1 (50) 0 1 (50)
4. Etiology and physiopathology 4 4 (100) 0 0
5. Comorbidities of AD 4 2 (50) 1 (25) 1 (25)
6. Health-related quality of life 2 2 (100) 0 0
7. Treatment and follow-up 19 14 (73.7) 2 (10.5) 3 (15.8)
AD: atopic dermatitis.
Table 2: Results regarding definition and diagnosis of AD.
Item Consensus(%)
Discrepancy
(%)
(i) AD can also develop de novo in adults or young adults, or even in advanced age 93.6
(ii) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the
skin components (cellular and extracellular components that form the skin barrier) 96.8
(iii) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the
immune system (innate and adaptative) 97.6
(iv) AD is a multifaceted disease that is derived from the interactions of multiple factors, including the
skin microbiome 89.6
(v) AD is a multifaceted disease that is derived from the interactions of multiple factors, including genetic
factors 98.4
(vi) AD is a multifaceted disease that is derived from the interactions of multiple factors, including
environmental factors 98.4
(vii) Currently, the diagnosis and assessment of the severity of AD are made on clinical grounds 97.6
(viii) -e clinical criteria defined by Hanifin and Rajka are used for the clinical diagnosis of AD 94.3
(ix) -e clinical presentation of AD depends on the age of the patients 92.8
(x)With greater frequency, children < 2 years of age and adults present involvement of the face and neck;
in addition, adults also present involvement of the flexor and extensor surfaces 94.3
(xi) Some forms of presentation seen in adults include dermatitis of the head and neck, chronic eczema of
the hands, and multiple zones of lichenification or prurigo 96.8
(xii) -e classification of “intrinsic” AD (not associated with IgE) and “extrinsic” AD (associated with
IgE) has practical implications related to specific avoidance strategies in the management of the disease 60.0
(xiii) -e blood eosinophil count is not a useful biomarker in AD 37.1∗
(xiv) Currently there are no validated biomarkers that help in the diagnosis of AD 83.2
AD: atopic dermatitis; IgE: immunoglobulin E. ​ ∗37.1% of disagreement.
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4. Discussion
-e aim of the Delphi method is to obtain an opinion, level
of agreement, or consensus on a current topic or concern
from among a group of specialists or experts. -is is an
iterative and anonymous process with controlled feedback
and analysis of the results widely used in health sciences. For
this study, the percentage of unanimity, consensus, majority,
and discrepancy has been decided taking into account the
standard percentages that are usually used for a Delphi
questionnaire of these characteristics and by agreement of
the entire scientific committee. Although the Delphi
methodology has been applied in various dermatological
diseases [23–31], no previous studies comprising a con-
sensus of opinion have been published on AD using the
Delphi technique. In a multicenter international project, a
Delphi study was conducted to reach consensus between
different stakeholders on a core set of domains and items for
registries of atopic eczema patients to collect data for re-
search focused on photo- and systemic immunomodulatory
therapies [32]. In this respect, given the paucity of Delphi
studies on AD, the present survey fills a gap in the literature.
With respect to the percentages of panelists having
completed the rounds of questions set, the data varies
depending on the characteristics of the study, including the
number of experts, survey distribution methods, number of
rounds, and face-to-face meetings. -e overall participation
rate in our study was 52.5%, but the percentage of partic-
ipants having completed the two Delphi rounds was 84%,
being in the upper band of the range over 60–80% reported
in the literature [33, 34]. In addition, the total number of 46
items was adequate, as high number of items is associated
with significantly lower response rates [35].
In the opinion of the panelists, consensus was obtained
regarding the consideration of AD as a multifaceted disease
caused by the interaction of multiple factors. Recent studies
of the etiopathogenesis of AD have highlighted the complex
interplay among skin barrier deficiency, immunological
derangement, which contributes to the development, pro-
gression, and chronicity of the disease [36]. Abnormalities in
filaggrin, another stratum corneum constituent, and tight
junctions induce and/or promote skin inflammation. -is
inflammation, in turn, can further deteriorate the barrier
function by downregulating a myriad of essential barrier-
maintaining molecules [36]. -e panel also agreed that the
diagnosis of AD remains clinical without a reliable bio-
marker to confirm the diagnosis or assess the severity of the
disease. Currently, biomarkers cannot be applied in daily
Table 3: Results regarding differential diagnosis, severity of AD, etiology and physiopathology, comorbidities, and health-related quality of
life.
Item Consensus(%)
Majority
(%)
Discrepancy
(%)
Differential diagnosis
(i) In certain situations, skin biopsy should be considered to exclude other conditions, such
as early stage T-cell cutaneous lymphoma, psoriasis, or dermatitis herpetiformis 99.1
Severity of AD
(i) -e SCORAD index is used to quantify the severity of the disease in order to assess the
comparative efficacy of treatments and progression of the disease in routine clinical practice 86.7
(ii) -e EASI score is a validated scale that is not used in routine clinical practice 58.1
Etiology and physiopathology
(i) A high percentage of patients with AD also present food allergy, allergic rhinitis, or
asthma 94.4
(ii) Treatments oriented to increase filaggrin expression can be useful in the management of
AD in a particular group of patients 93.3
(iii)Currently there is an unmet need in the treatment of moderate-severe AD 98.4
(iv) Biologic drugs are especially promising for adult patients with moderate or severe forms
of the disease 89.6
Comorbidities of AD
(i) AD in adults is frequently associated with allergic comorbidities 78.1
(ii) AD in children is frequently associated with allergic comorbidities 91.4
(iii) -e relative risk of suffering from immune-mediated inflammatory diseases such as
rheumatoid arthritis and chronic inflammatory bowel disease is higher in patients with AD
than in the general population
43.8∗
(iv) Children with AD are more prone to suffer from mental disorders such as depression,
anxiety, and behavior disorders 84.8
Health-related quality of life
(i) AD causes considerable psychological anxiety and results in a dramatic impact on the
quality of life for both patients and their families 91.2
(ii) -e usefulness of PO-SCORAD for the self-assessment of AD in children suggests the
importance of integrating the perspectives of the physician and the patient in the
management of AD
91.2
AD: atopic dermatitis; SCORAD: scoring atopic dermatitis; EASI: eczema area and severity index; PO-SCORAD: patient-oriented SCORAD. ​ ∗43.8% neither
agree nor disagree.
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practice for diagnosing AD, although they will play an in-
creasingly important role in AD research and personalized
medicine [37]. -ere were discrepancies regarding the
usefulness of the classification of intrinsic and extrinsic AD
as the basis of specific avoidance strategies, eosinophil count
as a biomarker of AD, and the use of EASI in clinical
practice.
-ere was also consensus about differences in the clinical
presentation of AD according to the patient’s age. Even
though many common features exist, there are significant
differences between the clinical characteristics of children,
adolescents, and adult AD subgroups [38]. Moreover, the
lack of standardization of outcome measures for clinical
signs of AD, such as clinical signs measured with a
physician-assessed instrument and symptoms measured
with a patient-assessed instrument or control of flares,
hampers comparison among studies [39]. Participants also
agreed on the need to perform a skin biopsy to exclude other
conditions, including early stage T-cell cutaneous lym-
phoma, psoriasis, or dermatitis herpetiformis. In this re-
spect, the clinical characteristics and the hallmark of Se´zary
syndrome, a leukemia variant of T-cell cutaneous lym-
phoma, often share striking similarities with AD [40].
In relation to comorbid conditions, allergic diseases in
adults and depression, anxiety, and behavioral disorders in
children were items for which consensus was obtained. A
recent meta-analysis of 35 studies found that children and
adolescents with AD had significantly higher risk of total
Table 4: Results regarding treatment and follow-up of patients with AD.
Item Consensus(%)
Majority
(%)
Discrepancy
(%)
Substances that should be avoided
(i) When the prick test is positive for any allergen with suspicion of clinical involvement,
avoidance of these allergens as far as possible may be a useful complementary measure 83.8
(ii) Patients with moderate-to-severe AD should follow a diet that does not include foods
testing positive in the prick test or prick-prick test and that are clinically relevant for the
patient
91.4
Topical and anti-inflammatory treatment
(i) -e use of wet wraps increases the effect of topical corticosteroids 90.4
(ii) Proactive “treatment”, for example, application for two times per week in long-term
follow-up, can help reduce new flares 85.6
(iii) Proactive “treatment” with application of tacrolimus ointment two times per week can
help reduce new flares 91.2
(iv) Simultaneous combination on the same location of topical glucocorticoids and topical
calcineurin inhibitors does not seem to be useful 72.4
(v) Based on results of clinical trials of crisaborole, this is not the treatment of choice for
severe AD 92.4
Antipruritic treatment
(i) -ere are no sufficient bibliographic references supporting the general use of first- and
second-generation antihistamines for treating pruritus in AD 85.7
(ii) First- and second-generation antihistamines, in general, are not useful for systemic
treatment of AD 64.8
Allergen-specific immunotherapy (allergen-SIT)
(i) Allergen-SIT has positive effects in some sensitized patients with AD 76.2
(ii) AD is not a contraindication for the use of immunotherapy in patients with allergic
respiratory diseases (allergic rhinoconjunctivitis, allergic bronchial asthma) 92.4
Systemic treatments
(i) With the current immune response modifiers, the therapeutic needs of patients with
severe AD are not sufficiently covered 97.6
(ii) In the treatment of severe AD, cyclosporine has an adequate risk-benefit ratio 80.0
(iii)With phototherapy, the therapeutic needs of patients with severe AD are not sufficiently
covered 92.8
(iv) In the treatment of severe AD, phototherapy has an adequate risk-benefit ratio 69.5
New systemic treatments
(i) Treatment with biologic drugs should be considered in patients with severe AD not
controlled with conventional systemic and topical treatment 93.6
(ii)-e objectives of these new biologic drugs should be targeting mainly cytokines involved
in -2 allergic inflammation such as IL-4, IL-5, IL-13, and IL-31 92.0
(iii) Dupilumab has the potential to become the new first-line reference treatment for
patients with moderate-to-severe AD who are candidates for systemic treatment (with or
without topical treatment)
90.4
(iv) According to results of phase II studies, JAK inhibitors will be a future treatment of AD 60.0∗
AD: atopic dermatitis; SIT: specific immunotherapy; IL: interleukin; JAK : Janus kinase. ​ ∗60.0% neither agree nor disagree.
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mental disorders than those without AD (odds ratio [OR]
1.65; 95% confidence interval [CI] 1.46–1.86), with an ab-
solute risk of 12.6% [41]. Also, AD was recognized as the
cause of considerable psychological anxiety. In fact, psy-
chological stress is a significant contributor to AD disease
course through its direct and indirect effects on immune
response, cutaneous neuropeptide expression, and skin
barrier function [42].
Consensus regarding treatment included the use of wet
wraps to enhance the effect of topical corticosteroids, the
use of proactive treatment in the affected area to reduce
new flares, the recognition that crisaborole is not the
treatment of choice for severe AD, the adequate benefit-risk
ratio of cyclosporine in severe AD, the role of biologic
drugs, targeting cytokines involved in allergic inflamma-
tion caused by-2 helper lymphocytes, and the potential of
dupilumab to become the new first-line treatment in pa-
tients with moderate-to-severe AD [43, 44]. A consensus
was also reached on how to interpret skin prick test results.
-ere was discrepancy in relation to the statement that
first- and second-generation antihistamines are generally
not useful in the systemic treatment of AD. Short-term,
intermittent use of sedating antihistamines may be bene-
ficial in the setting of sleep loss secondary to itch [45] but
they reduce rapid eye movement (REM) sleep, produce
daytime somnolence, impair learning, and reduce work
efficiency [46]. It has been postulated that second-gener-
ation antihistamines may have anti-inflammatory effects.
In human keratinocytes, histamine decreases the formu-
lation of tight junctions and the expression of filaggrin, a
gene responsible for AD, via histamine H1 receptor (H1R)
[47]. Furthermore, histamine regulates IL-31, a cytokine
involving the skin barrier and pruritus, through H1R and
induces the production of thymus and activation-regulated
chemokine (TARC) via H4R [47]. Recently, in a ran-
domized, double-blind, placebo-controlled, parallel-group
study, a novel selective H4R antagonist, ZPL-3893787,
showed significant reductions of EASI and SCORAD scores
as compared with placebo, but a nonsignificant difference
in the reduction of pruritus [48].
-e results of the present study should be interpreted
taking into account the fact that responses to the ques-
tionnaire reflect what the specialists would do in the different
scenarios posed by each question, which may differ slightly
from their clinical practice. However, the Delphi method
allowed exploring systematically different clinical, diag-
nostic, and treatment aspects of patients with AD, based on
the qualified opinion of dermatology and allergology experts
in the field. -ere is no diagnostic test or biomarkers to
direct treatment or to assess the severity of the disease, and
many therapeutic challenges remain. -e extent to which
activation of immune pathways in addition to -2 signaling
contributes to AD pathogenesis remains unknown [49], as
well as whether new medications directed against targets
believed to lead to AD will prove to be effective without
significant risk.
In summary, this was a Delphi survey study of a sample
of dermatology and allergology experts in the care of patients
with AD. -e present consensus document contributes as a
reference framework for the care of adult patients with
moderate-to-severe AD in clinical practice.
Data Availability
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